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Introduction: According to recent evidence about boosted protease inhibitors (PIs/r)-simplified regimens, the combination of
3TC and DRV/r 800/100 mg could represent a feasible option for optimizing antiretroviral therapy (ART) in treatment-
experienced HIV patients.
Patients and Methods: We retrospectively evaluated patients switching to 3TCDRV/r, with at least six months of viral
suppression, no resistance mutation to DRV or 3TC and not HBV-coinfected: incidence of ART discontinuation and of virological
failure (VF: 2 consecutive HIV-RNA determinations49 cps/mL or a single one]1000 cps/mL) and the probability of remaining
discontinuation-free during one-year follow-up (FU), as well as changes in laboratory parameters at 1, 3, 6 and 12 months were
estimated.
Results: We included 94 patients: 74 males, mostly MSM (39.4%), with 49 years old, 9 years of HIV disease, 8 years of ART
(median values). Median nadir CD4 count and zenith viral load (log10) were 194 cells/mL and 4.90, respectively. Ten patients
were HCV-coinfected and 38 had at least a previous VF. Seventy-four patients were on an NRTIs-based triple regimen (mainly
TDF/FTC or 3TC/ABC) whereas 14 on another PI-based dual therapy (mainly LPV/r). Incidence of treatment discontinuation was
12.4 per 100 patients-year follow-up (PYFU), but only 2 patients experienced a VF (3.5 per 100 PYFU). Mean time free from
discontinuation was 5 years (95% CI 46), with a cumulative one-year estimated probability of staying on 3TCDRV/r of 85.9%.
At three months, a trend of increased CD4 cells count (42 cells/mL, p 0.059) was observed, but not confirmed at later time
point; an increase of total cholesterol (TC,17mg/dL, p 0.008) and LDL (19 mg/dL, p 0.002), and a decreased level of AST and
ALT (2 UI/L, p 0.045; 5 UI/L, p 0.009, respectively) were also detected. Total bilirubin was reduced (0.71 mg/dL, p 0.038).
At 6 and 12 months, alteration of lipid profile was similar, with also an increased TC/HDL ratio (0.48, p0.030, at six months)
and HDL/LDL ratio (0.04, p0.035, at 12 months). A significant decrease in ALT levels (6 UI/L, 0.013) and a diminishing
trend for AST and total bilirubin, as well as a significant increase in renal function (GFR4mL/min, p 0.048) were observed at 12
months.
Conclusions: These observations on 3TCDRV/r-based dual therapy simplification in virologically suppressed patients show a
good profile of efficacy and safety. An extended FU time is needed in order to establish the real impact of this promising
therapeutic choice.
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